Agilent Technologies
Inc. announced that it has entered into a comarketing agreement with Molecular
Discovery Ltd. to provide biopharmaceutical researchers with an advanced
metabolite-identification platform. The companies will comarket the combined
assets of Agilent’s high-resolution liquid chromatography/mass spectrometry
(LC/MS) technology and Molecular Discovery’s Mass-MetaSite software to enable
superior identification and analysis of complex biological mixtures.
This
comarketing program provides customers with a turnkey solution that bridges the
gap between sophisticated laboratory software and hardware capabilities. The
analytical benefits of Agilent’s high-resolution instruments, integrated with
Molecular Discovery’s robust predictive metabolite-identification software tools,
will advance drug research and discovery by enabling the decisive
identification and conversion of large volumes of data into usable information.
Source: Agilent Technologies Inc.
